Skip to main content
. 2022 May 3;18:953–964. doi: 10.2147/NDT.S358851

Figure 4.

Figure 4

Changes in CD19+ and CD19+CD27+ B lymphocytes in MuSK-MG patients after treatment with low-dose rituximab at 1, 3, and 6 months. (A) CD19+ B cells were depleted by rituximab and remained <1% at 6 months. (B) CD19+CD27+ B-cell counts were decreased from 5.88 (4.00–16.48%) at baseline to 0.11% (0.00–0.22%) at 6 months. The difference is statistically significant. The upper and lower short black lines represent the maximum and minimum values, respectively. The long black line in the middle represents the median values. *P<0.05; **P<0.01, vs baseline.

Abbreviations: MuSK, muscle-specific tyrosine kinase; MG, myasthenia gravis.